PURPOSE: To report on the patient population, classification, treatment options, and prognosis of pulmonary hypertension in Manitoba.
METHODS: Prospective study following a group of patients in Manitoba diagnosed with pulmonary artery hypertension from December 2000 to December 2005. Diagnosis of pulmonary artery hypertension was determined by right heart catheterization as defined by the National Institute of Health as mean pulmonary artery pressure of greater than 25 mmHg at rest or greater than 30 mmHg with exercise. Patients were followed with pulmonary function testing and six-minute walk tests; all medications were recorded. Clinical severity was graded according to the World Health Organization functional classification.
RESULTS: In December 2000 there were 60 live patients enrolled, in December 2005 there were 48 live patients with pulmonary hypertension in the registry. Ten were male with a mean age of 59 years +/- 9.86 and 38 were females with a mean age of 52.3 +/- 16.8 years. Sub-diagnosis was as follows: 17 cases were idiopathic pulmonary hypertension, 20 cases were related to collagen vascular disease, 3 cases were related to congenital pulmonary shunts, and 4 were related to chronic thromboembolic disease. Fourteen patients were classified as WHO functional class III, and 7 were WHO functional class IV. Thirty-four patients were being treated with Bosentan, and 3 patients were treated with Flolan, 5 patients were on combination therapy.
CONCLUSION: Pulmonary artery hypertension is a serious disease with significant burden of illness and mortality in Manitoba. Currently there are 70 patients in the Manitoba database.
CLINICAL IMPLICATIONS: The results from this study will provide the necessary frame work upon which further studies can be launched. These include the effectiveness of specific and combination therapies in treatment of idiopathic disease and other subtypes.
DISCLOSURE: Renelle Myers, No Financial Disclosure Information; No Product/Research Disclosure Information